Author: Fiona Craig

Avingtrans’ Advanced Engineering Systems division (LSE:AVG) has recorded strong momentum in global nuclear markets, securing more than £10 million in nuclear-related orders since the beginning of the year. Among the contracts is a £3 million deal to supply a reactor water cleanup pump for Iberdrola’s Cofrentes nuclear plant in Spain, alongside long-lead prototype pump components for emerging small-scale nuclear technologies.

The company highlighted its involvement across the full nuclear lifecycle—from legacy asset support and life extension to new build, fusion, and decommissioning—as a key advantage in capturing growth driven by energy security and decarbonisation priorities. Increasing electricity demand from energy-intensive data centres is also expected to accelerate interest in small modular reactors (SMRs), an area where Avingtrans is already working on prototype development with a leading SMR partner.

Avingtrans’ portfolio of businesses, including Booth Industries, Hayward Tyler, Energy Steel, HT Fluid Handling, Metalcraft, and Ormandy Rycroft, positions it across both nuclear infrastructure and data centre cooling solutions. This broad exposure supports a growing project pipeline and underpins management’s confidence in meeting current market expectations.

The company’s outlook is supported by solid financial performance and recent contract wins, although valuation metrics suggest the shares may be somewhat stretched. Technical indicators point to a more neutral trend, and limited disclosure from earnings calls constrains deeper insight into management’s forward guidance.

More about Avingtrans

Avingtrans plc is a UK-based engineering group supplying equipment, systems, and services to energy, medical, and industrial markets worldwide. Its operations span performance-critical pumps and motors, nuclear components, pressure vessels, specialist access systems, HVAC equipment, and advanced imaging technologies, serving both infrastructure and high-tech applications across global markets.

Animalcare Group (LSE:ANCR) has agreed to a recommended takeover by CCP PAW 2 Limited, an indirect subsidiary of Charterhouse Capital Partners, through a UK scheme of arrangement. The offer values the business at about £235.2 million, with shareholders set to receive 336 pence in cash per share—representing a premium of up to 36% compared with recent market prices.

In addition to the cash option, eligible investors may choose to roll over a significant portion of their holdings into unlisted Topco Units via an aggregator structure, receiving Aggregator Interests instead of full cash consideration. While Animalcare’s board has unanimously backed the cash offer as fair and reasonable, it has not expressed a recommendation regarding the alternative structure. Charterhouse believes that taking the company private will allow for increased investment in research and development, operational improvements, and acquisition-led expansion within the animal health sector.

From an outlook perspective, Animalcare benefits from a stable financial position and the positive implications of the proposed transaction. However, valuation remains a consideration due to a negative price-to-earnings ratio. Technical indicators suggest moderate upside potential, while the company’s strategic direction and board confidence provide additional support.

More about Animalcare

Animalcare Group is an international animal health pharmaceuticals business with a diversified portfolio of veterinary products and limited reliance on any single product line. The company operates across Europe and Australasia, focusing on growth in the expanding animal health market through a combination of in-house R&D and targeted acquisitions, including deals such as Randlab.

Nativo Resources (LSE:NTVO) has announced new assay results from underground sampling at its Bonanza Gold Mine, part of the Tesoro concession in southern Peru. Certified laboratory testing returned standout grades of up to 73.4 g/t gold, alongside notable silver values, confirming the presence of bonanza-grade mineralisation within structurally controlled zones of the Bonanza vein system.

These findings strengthen the company’s geological interpretation, demonstrating continuity of high-grade mineralisation from surface exposures into underground workings and pointing to potential extensions at depth. Together with earlier sampling results and existing stockpiled material, the data support a selective narrow-vein mining strategy. This approach is aimed at reducing dilution, focusing on high-margin zones, and enabling early-stage cash flow as the company moves toward initial production and sales targeted for the second quarter of 2026.

Despite encouraging operational progress, the company’s financial profile remains a key constraint, with ongoing losses, negative equity, relatively high leverage compared to asset levels, and continued cash burn. Market indicators offer limited support, reflecting a short-term recovery in the share price, though momentum appears stretched and the stock remains below its 200-day average. Valuation also remains challenging due to negative earnings and the absence of dividend support.

More about Nativo Resources plc

Nativo Resources plc is a London-listed gold mining company focused on projects in Peru. The company is engaged in primary gold extraction, ore processing, and the recovery of gold from tailings. Its near-term strategy centres on scaling production at the Tesoro Gold Concession, including the Bonanza and Morrocota mines, as it works toward establishing sustainable operations and revenue generation.

CAB Payments (LSE:CABP) has received a revised non-binding and final indicative cash offer from StoneX Group at 110 pence per share, valuing the business at around £287 million. The proposal implies a premium of 52% to the undisturbed share price prior to an earlier approach, 43% above the 52-week high, and 29% higher than the existing firm offer from the Helios Consortium.

Following discussions with its advisers, the company’s independent board stated it would be inclined to recommend a formal offer from StoneX at this level, subject to satisfactory due diligence and agreement on final terms. The board has also encouraged the Helios Consortium to engage with StoneX, noting the enhanced value for shareholders. However, it emphasised that there is no guarantee a binding offer will materialise and advised investors not to take any action at this stage.

From a financial perspective, the company presents a mixed outlook. While it maintains a solid balance sheet with relatively low leverage, performance has been impacted by volatile cash flows and inconsistent revenue and margin trends. Market indicators offer some support, with the share price trading above key moving averages, while valuation appears reasonable on a price-to-earnings basis, though the absence of dividend yield data limits further assessment.

More about CAB Payments Holdings Limited

CAB Payments Holdings PLC operates within the financial services sector, specialising in cross-border payments and foreign exchange solutions. The company focuses on enabling transactions in emerging and less accessible markets, providing infrastructure and services to financial institutions and corporate clients with complex international payment requirements.

Mila Resources (LSE:MILA) has announced early results from its Q1 2026 reverse circulation drilling programme at the Yarrol Gold Project in Queensland, confirming gold mineralisation at the southernmost drill locations at Yarrol North. These results extend the known strike length of the system to more than than 500 metres, with mineralisation remaining open in all directions. Broad zones of gold, including higher-grade intercepts at the southern edge, are being incorporated—alongside pending assay data from additional infill and step-out drilling—into the dataset required for a maiden JORC-compliant mineral resource estimate.

At the Monal West licence, initial rock chip sampling at the Jazza target has identified anomalous gold, copper, and silver values, accompanied by elevated levels of molybdenum, zinc, and tungsten. This geochemical profile is consistent with the presence of a deeper porphyry system and related epithermal mineralisation. Backed by a significant inherited induced polarisation (IP) geophysical anomaly, the findings point to the possibility of a larger mineralised system. Mila plans to carry out targeted ground-based geophysical surveys to refine drill targets and advance both Yarrol and Monal West toward resource definition, supporting the broader growth potential of its Queensland assets.

The company’s outlook remains constrained by its financial position, characterised by a lack of revenue, ongoing losses, and continued negative free cash flow, alongside weak technical indicators such as a share price below key moving averages and a negative MACD. However, a relatively low level of debt and a stable equity base provide some underlying support, even as valuation remains difficult to justify given negative earnings and the absence of dividend yield.

More about Mila Resources

Mila Resources Plc is a London-listed gold exploration company focused on developing gold and copper projects in Queensland, Australia. Its primary asset, the Yarrol Gold Project, is advancing toward an initial JORC-compliant resource estimate, supported by additional exploration across its wider licence portfolio, including the prospective Monal West porphyry corridor.

Hays plc (LSE:HAS) has published its trading update for the quarter ended 31 March 2026, offering insight into recent business performance. The statement is available via the London Stock Exchange and the company’s investor relations platform, and has also been filed with the UK regulator’s National Storage Mechanism.

The group will host a conference call for analysts and investors on 16 April 2026 to discuss the latest developments in more detail. A recorded replay will be made accessible through its investor results centre, reflecting Hays’s ongoing commitment to maintaining open communication with the market.

From an outlook perspective, the company faces pressure from weak technical indicators, with the share price trading below key moving averages and a negative MACD signal. Valuation also appears stretched, with a notably high price-to-earnings ratio of 748.65. Financial performance presents a mixed picture, with declining revenue and continued losses offset to some extent by improvements in free cash flow.

More about Hays plc

Hays plc is a global recruitment and workforce solutions provider, specialising in placing skilled professionals across a wide range of industries. The company operates across both permanent and temporary hiring markets, serving private and public sector clients in multiple regions worldwide.

Oriole Resources (LSE:ORR) has released new exploration findings from its 90%-owned Eastern Central Licence Package in Cameroon, located close to its 1.23-million-ounce Mbe gold resource. Ongoing work across the Ndom, Pokor, and Niambaram licences is reinforcing the potential for a large-scale gold system that could meaningfully increase the company’s overall resource base if current targets are validated.

At the Ndom licence, selective rock-chip sampling has delivered grades of up to 17 grams per tonne gold from quartz veins that display structural characteristics similar to those seen at Mbe. These results have led to the planning of additional follow-up exploration. Meanwhile, at Pokor and Niambaram, soil and rock-chip programmes have identified lower-grade anomalies, with further mapping and assay work scheduled through 2026 to refine drill targets and guide future exploration priorities.

From a financial standpoint, the company remains constrained by its lack of revenue generation and continued cash outflows, although it benefits from a relatively low level of debt. Technical signals provide some support, indicating moderate momentum, but valuation remains limited by negative earnings and the absence of dividend indicators.

More about Oriole Resources PLC

Oriole Resources PLC is an AIM-listed gold exploration and development company with a focus on Central and West Africa. Its flagship asset is the Mbe orogenic gold project in Cameroon, which hosts an inferred mineral resource of 1.23 million ounces. The company also holds a broader portfolio of early-stage exploration licences within the Eastern Central Licence Package, targeting further discoveries to build scale in the region.

Creo Medical (LSE:CREO) has agreed to sell its UK-based manufacturing division to a newly established company led by its current manufacturing management team, as part of a management buyout. Around 25 employees will transfer to the new entity, with production of Creo’s devices continuing under an outsourced model. The transaction reflects the company’s transition toward a leaner structure focused on product development and commercialisation, while maintaining operational continuity and technical expertise.

The outsourcing arrangement is expected to deliver annual cost savings exceeding £1 million, representing an additional 15% reduction based on the FY25 closing run-rate on a pro forma basis. This builds on an estimated 40% cost reduction already achieved since FY24. By maintaining a close relationship with the new manufacturing business—where CEO Craig Gulliford will take on a non-executive role—Creo aims to scale production efficiently while concentrating resources on innovation and sales growth, reinforcing its position in the advanced medical device sector.

Despite these operational efficiencies, the company’s financial outlook remains under pressure, with declining revenues, significant losses, and continued cash outflows. Market indicators offer some support, with a strong upward trend and positive MACD, although a high RSI suggests the stock may be overbought in the near term. The overall valuation impact is unclear, as key metrics such as price-to-earnings ratio and dividend yield are not currently available.

More about Creo Medical

Creo Medical Group is a UK-based medical technology company specialising in minimally invasive electrosurgical devices used in endoscopic procedures for pre-cancerous and cancerous conditions. Its CROMA platform, built on Kamaptive technology, combines multiple energy sources—including radiofrequency and microwave—into a single system to enable precise cutting, coagulation, dissection, and ablation. The company is focused on advancing a portfolio of patented solutions aimed at improving clinical outcomes while reducing the invasiveness and cost of surgical and endoscopic treatments.